Guardant Health attends the UBS Genomics 2.0 and MedTech Innovations Summit | business

0

REDWOOD CITY, Calif .– (BUSINESS WIRE) – Aug. August 2021–

Guardant Health, Inc. (Nasdaq: GH), a leader in precision oncology, announced today that it will be attending the upcoming UBS Genomics 2.0 and MedTech Innovations Summit.

Guardant Health management is expected to participate in a fireside chat on Tuesday, August 10 at 4:00 p.m. Pacific Time / 7:00 p.m. Eastern Time. A live and archived webcast of the presentation can be viewed in the Investors section of the company’s website at www.guardanthealth.com.

About Guardant Health

Guardant Health is a leading precision oncology company focused on helping fight cancer worldwide through the use of its proprietary tests, extensive data sets and advanced analytics. Guardant Health’s oncology platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes, and reduce healthcare costs at all stages of cancer care. Guardant Health has commercially launched the Guardant360 ®, Guardant360 CDx, Guardant360 TissueNext ™, Guardant360 Response ™, and GuardantOMNI ® tests for advanced cancer patients and Guardant Reveal ™ for early cancer patients. These tests are fueling the development of its LUNAR screening program, which aims to meet the needs of asymptomatic individuals eligible for cancer screening.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210806005507/en/

CONTACT: Investor contact:

Carrie Mendivil

[email protected] Media contact:

Anna Czene

[email protected]

KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA

INDUSTRY KEYWORD: BIOTECHNOLOGY OTHER HEALTH HEALTH PHARMACEUTICAL ONCOLOGY

SOURCE: Guardant Health, Inc.

Copyright Business Wire 2021.

PUB: 6/8/2021 4:15 p.m. / DISC: 6/8/2021 4:16 p.m.

http://www.businesswire.com/news/home/20210806005507/en

Copyright Business Wire 2021.

Leave A Reply

Your email address will not be published.